Chronic myeloid leukemia associated with pure red cell aplasia and terminating in promyelocytic transformation

Mijović, Aleksandar; Rolović, Z; Novak, Angelina; Biljanović-Paunović, L; Tomin, Dragica

doi:10.1002/ajh.2830310211

Cited by 7 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our search for reports on promyelocytic crisis arising during CML yielded but a few cases (table 1), suggesting that promyelocytic crisis is rare [6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28]. Most affected patients died of severe bleeding caused by the complication of disseminated intravascular coagulation.…”

Section: Discussionmentioning

confidence: 99%

Promyelocytic Crisis of Chronic Myelogenous Leukaemia during Imatinib Mesylate Treatment

Oku

Imamura²,

Nagata

et al. 2006

Acta Haematol

View full text Add to dashboard Cite

An untreated 66-year-old woman with chronic myelogenous leukaemia (CML) in the chronic phase was initially given imatinib mesylate, rapidly achieving a good cytogenetic response with treatment. However, acute promyelocytic leukaemia complicated by a disseminated intravascular coagulation occurred 9 months after beginning imatinib treatment. Promyelocytic crisis of CML was diagnosed by demonstration of both BCR/ABL and PML/RARα chimeric genes in leukaemic cells by karyotypic and fluorescence in situ hybridization analysis. Clonal evolution with addition of the PML/RARα translocation may have arisen in the early chronic phase of CML, with expansion of this clone during imatinib treatment. Promyelocytic crisis of CML is rare; furthermore, we know of no previous report of promyelocytic crisis occurring during treatment with imatinib.

show abstract

Section: Discussionmentioning

confidence: 99%

Promyelocytic Crisis of Chronic Myelogenous Leukaemia during Imatinib Mesylate Treatment

Oku

Imamura²,

Nagata

et al. 2006

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…Although uncommon, APL cases without t (15;17) may have complex translocations involving chromosomes 15 and 17 and a nontraditional chromosome partner, resulting in a submicroscopic insertion of RARA into PML [ 30 ]. In 3 of the reviewed cases, the promyelocytic blast crisis diagnosis was based on morphologic, immunophenotypic, and/or flow cytometric findings alone; no disease-defining cytogenetic or molecular results were reported [ 20 , 21 , 24 ]. For the purpose of this review, all cases were considered promyelocytic blast crisis of CML, even in the absence of defining reported cytogenetic/molecular evidence.…”

Section: Discussionmentioning

confidence: 99%

PML-RARA Fusion Transcripts Detectable 8 Months prior to Promyelocytic Blast Crisis in Chronic Myeloid Leukemia

Wolanin

McCall

Pettenati

et al. 2020

Case Reports in Hematology

View full text Add to dashboard Cite

Promyelocytic blast crisis arising from chronic myeloid leukemia (CML) is rare. We present a 40-year-old male who developed promyelocytic blast crisis 17 months after CML diagnosis, confirmed by the presence of the t(15;17) and t(9;22) translocations in the leukemic cells. Preserved nucleic acids from routine BCR-ABL1 testing provided a unique opportunity to evaluate clonal progression over time. Retrospective analysis demonstrated PML-RARA fusion transcripts were first detectable 8 months prior to blast crisis presentation. A review of 21 cases of promyelocytic blasts crisis published in the literature reveals a male predominance with earlier age at onset as compared to females. Interestingly, TKI therapy during chronic phase did not impact the time interval between diagnosis and promyelocytic blast crisis. Treatment with standard acute promyelocytic leukemia regimens provides more favorable outcomes with complete molecular remission. Although rare, it is important to consider a promyelocytic blast crisis when evaluating for transformation of CML due to its effective treatment with specific therapies.

show abstract

“…It may precede, coincide or follow the development of CGL. PRCA may herald the transformation of CGL into acute phase ( Mijovic et al . 1989 ).…”

Section: Introductionmentioning

confidence: 99%

Pure red cell aplasia in a patient with chronic granulocytic leukaemia treated with interferon-α

Hirri

Green

2000

Clinical &Amp; Laboratory Haematology

View full text Add to dashboard Cite

Interferon-alpha has been shown to improve survival in patients with chronic granulocytic leukaemia, therefore it is increasingly becoming part of the standard treatment of this condition. Interferon has a wide variety of side-effects. Pure red cell aplasia has been reported in a few cases of chronic granulocytic leukaemia but this usually heralds the onset of the transformation to the acute phase. This paper reports a possible, and not previously reported, side-effect of interferon-alpha in a patient with chronic granulocytic leukaemia.

show abstract

Chronic myeloid leukemia associated with pure red cell aplasia and terminating in promyelocytic transformation

Cited by 7 publications

References 11 publications

Promyelocytic Crisis of Chronic Myelogenous Leukaemia during Imatinib Mesylate Treatment

Promyelocytic Crisis of Chronic Myelogenous Leukaemia during Imatinib Mesylate Treatment

PML-RARA Fusion Transcripts Detectable 8 Months prior to Promyelocytic Blast Crisis in Chronic Myeloid Leukemia

Pure red cell aplasia in a patient with chronic granulocytic leukaemia treated with interferon-α

Contact Info

Product

Resources

About